Skip to main content
Top
Published in: BMC Gastroenterology 1/2014

Open Access 01-12-2014 | Research article

Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events

Authors: Ana Ruigómez, Saga Johansson, Péter Nagy, Mar Martín-Pérez, Luis A García Rodríguez

Published in: BMC Gastroenterology | Issue 1/2014

Login to get access

Abstract

Background

The aim of this study was to analyse the risk of uncomplicated peptic ulcer disease (PUD) in a cohort of new users of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK primary care setting.

Methods

New users of low-dose ASA for secondary prevention of cardiovascular events, aged 50-84 years in 2000-2007, were identified from The Health Improvement Network. Among those 38,975 individuals, 309 patients were considered to be incident cases of uncomplicated PUD. Incidence of uncomplicated PUD was calculated and a nested case–control analysis adjusted for potential confounding factors was performed to calculate the odds ratios (ORs) for the association of potential risk factors with uncomplicated PUD.

Results

The crude incidence of uncomplicated PUD was 1.41 per 1000 person-years (95% confidence interval [CI], 1.26-1.58). Individuals with a history of PUD were more likely to develop uncomplicated PUD than those without such a history (hazard ratio [HR], 2.22, 95% CI, 1.60-3.09). In nested case–control analyses, the risk of uncomplicated PUD was associated with current use of non-steroidal anti-inflammatory drugs, oral steroids or acid suppressants. Other risk factors for developing uncomplicated PUD included smoking, stress, depression, anaemia and social deprivation.

Conclusion

Our results indicate that several risk factors significantly increase the risk of development of uncomplicated PUD in new users of low-dose ASA. Therefore, physicians should monitor ASA users for gastrointestinal symptoms and signs of ulcer, particularly if they have additional risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP: ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012, 60: 645-681. 10.1016/j.jacc.2012.06.004.CrossRefPubMed Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP: ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012, 60: 645-681. 10.1016/j.jacc.2012.06.004.CrossRefPubMed
2.
go back to reference Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte Op Reimer WJM, Vrints C, Wood D, Zamorano JL, Zannad F, Cooney MT, Bax J, Baumgartner H, et al: European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 33: 1635-1701. 10.1093/eurheartj/ehs092.CrossRefPubMed Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte Op Reimer WJM, Vrints C, Wood D, Zamorano JL, Zannad F, Cooney MT, Bax J, Baumgartner H, et al: European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 33: 1635-1701. 10.1093/eurheartj/ehs092.CrossRefPubMed
3.
go back to reference Cea Soriano L, García Rodríguez LA: Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol. 2010, 1: 126-135. 10.3389/fphar.2010.00126.CrossRefPubMedPubMedCentral Cea Soriano L, García Rodríguez LA: Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol. 2010, 1: 126-135. 10.3389/fphar.2010.00126.CrossRefPubMedPubMedCentral
4.
go back to reference García Rodríguez LA, Hernández-Díaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004, 159: 23-31. 10.1093/aje/kwh005.CrossRefPubMed García Rodríguez LA, Hernández-Díaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004, 159: 23-31. 10.1093/aje/kwh005.CrossRefPubMed
5.
go back to reference Barkun A, Leontiadis G: Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010, 123: 358-366. 10.1016/j.amjmed.2009.09.031. e352CrossRefPubMed Barkun A, Leontiadis G: Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010, 123: 358-366. 10.1016/j.amjmed.2009.09.031. e352CrossRefPubMed
6.
go back to reference Martín-Merino E, Johansson S, Bueno H, García Rodríguez LA: Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Prag Obs Res. 2012, 3: 1-9. Martín-Merino E, Johansson S, Bueno H, García Rodríguez LA: Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Prag Obs Res. 2012, 3: 1-9.
7.
go back to reference Pratt S, Thompson VJ, Elkin EP, Naesdal J, Sorstadius E: The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010, 10: 281-288. 10.2165/11584410-000000000-00000.CrossRefPubMed Pratt S, Thompson VJ, Elkin EP, Naesdal J, Sorstadius E: The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010, 10: 281-288. 10.2165/11584410-000000000-00000.CrossRefPubMed
8.
go back to reference Moberg C, Naesdal J, Svedberg L-E, Duchateau D, Harte N: Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient. 2011, 4: 103-113. 10.2165/11589200-000000000-00000.CrossRefPubMed Moberg C, Naesdal J, Svedberg L-E, Duchateau D, Harte N: Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient. 2011, 4: 103-113. 10.2165/11589200-000000000-00000.CrossRefPubMed
9.
go back to reference Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G: Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. Int J Cardiol. 2012, 156: 69-75. 10.1016/j.ijcard.2010.10.027.CrossRefPubMed Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G: Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with Low Dose Aspirin: The UGLA survey. Int J Cardiol. 2012, 156: 69-75. 10.1016/j.ijcard.2010.10.027.CrossRefPubMed
10.
go back to reference Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005, 45: 456-459. 10.1016/j.jacc.2004.11.041.CrossRefPubMed Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005, 45: 456-459. 10.1016/j.jacc.2004.11.041.CrossRefPubMed
11.
go back to reference García Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S: Discontinuation of low dose aspirin and risk of myocardial infarction: case–control study in UK primary care. BMJ. 2011, 343: d4094-10.1136/bmj.d4094.CrossRefPubMedCentral García Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S: Discontinuation of low dose aspirin and risk of myocardial infarction: case–control study in UK primary care. BMJ. 2011, 343: d4094-10.1136/bmj.d4094.CrossRefPubMedCentral
12.
go back to reference García Rodríguez LA, Cea Soriano L, Hill C, Johansson S: Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011, 76: 740-746. 10.1212/WNL.0b013e31820d62b5.CrossRefPubMed García Rodríguez LA, Cea Soriano L, Hill C, Johansson S: Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology. 2011, 76: 740-746. 10.1212/WNL.0b013e31820d62b5.CrossRefPubMed
13.
go back to reference Lassen A, Hallas J, Schaffalitzky de Muckadell OB: Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol. 2006, 101: 945-953. 10.1111/j.1572-0241.2006.00518.x.CrossRefPubMed Lassen A, Hallas J, Schaffalitzky de Muckadell OB: Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol. 2006, 101: 945-953. 10.1111/j.1572-0241.2006.00518.x.CrossRefPubMed
14.
go back to reference Hernández-Diaz S, Martín-Merino E, García Rodríguez LA: Risk of complications after a peptic ulcer diagnosis: effectiveness of proton pump inhibitors. Dig Dis Sci. 2013, 58: 1653-1662. 10.1007/s10620-013-2561-9.CrossRefPubMed Hernández-Diaz S, Martín-Merino E, García Rodríguez LA: Risk of complications after a peptic ulcer diagnosis: effectiveness of proton pump inhibitors. Dig Dis Sci. 2013, 58: 1653-1662. 10.1007/s10620-013-2561-9.CrossRefPubMed
15.
go back to reference Miyake K, Kusunoki M, Ueki N, Nagoya H, Kodaka Y, Shindo T, Kawagoe T, Gudis K, Futagami S, Tsukui T, Nakamura H, Sakamoto C: Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for NSAIDs-associated ulcers complication. Dig Endosc. 2013, 25: 25-31. 10.1111/j.1443-1661.2012.01334.x.CrossRefPubMed Miyake K, Kusunoki M, Ueki N, Nagoya H, Kodaka Y, Shindo T, Kawagoe T, Gudis K, Futagami S, Tsukui T, Nakamura H, Sakamoto C: Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for NSAIDs-associated ulcers complication. Dig Endosc. 2013, 25: 25-31. 10.1111/j.1443-1661.2012.01334.x.CrossRefPubMed
16.
go back to reference Cai S, García Rodríguez LA, Massó-González EL, Hernández-Diaz S: Uncomplicated peptic ulcer in the UK: trends from 1997–2005. Aliment Pharmacol Ther. 2009, 30: 1039-1048. 10.1111/j.1365-2036.2009.04131.x.CrossRefPubMed Cai S, García Rodríguez LA, Massó-González EL, Hernández-Diaz S: Uncomplicated peptic ulcer in the UK: trends from 1997–2005. Aliment Pharmacol Ther. 2009, 30: 1039-1048. 10.1111/j.1365-2036.2009.04131.x.CrossRefPubMed
17.
go back to reference Bourke A, Dattani H, Robinson M: Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004, 12: 171-177. 10.14236/jhi.v12i3.124.PubMed Bourke A, Dattani H, Robinson M: Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004, 12: 171-177. 10.14236/jhi.v12i3.124.PubMed
18.
go back to reference Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL: Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007, 16: 393-401. 10.1002/pds.1335.CrossRefPubMed Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL: Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007, 16: 393-401. 10.1002/pds.1335.CrossRefPubMed
19.
go back to reference Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM: A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp. 1996, ᅟ: 75-79. Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM: A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp. 1996, ᅟ: 75-79.
20.
go back to reference O’Neil M, Payne C, Read J: Read Codes Version 3: a user led terminology. Methods Inf Med. 1995, 34: 187-192.PubMed O’Neil M, Payne C, Read J: Read Codes Version 3: a user led terminology. Methods Inf Med. 1995, 34: 187-192.PubMed
22.
go back to reference Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andriulli A, Scarcelli C, Di Mario F: Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004, 20: 1091-1097. 10.1111/j.1365-2036.2004.02246.x.CrossRefPubMed Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andriulli A, Scarcelli C, Di Mario F: Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004, 20: 1091-1097. 10.1111/j.1365-2036.2004.02246.x.CrossRefPubMed
23.
go back to reference Lau JY, Sung JJ, Metz DC, Howden CW: Systematic review of the epidemiology of complicated peptic ulcer: incidence, recurrence, risk factors and mortality. Gastroenterology. 2008, 134 (4 Suppl 1): A32- Lau JY, Sung JJ, Metz DC, Howden CW: Systematic review of the epidemiology of complicated peptic ulcer: incidence, recurrence, risk factors and mortality. Gastroenterology. 2008, 134 (4 Suppl 1): A32-
24.
go back to reference García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S: Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011, 123: 1108-1115. 10.1161/CIRCULATIONAHA.110.973008.CrossRefPubMed García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S: Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011, 123: 1108-1115. 10.1161/CIRCULATIONAHA.110.973008.CrossRefPubMed
25.
go back to reference Udd M, Miettinen P, Palmu A, Heikkinen M, Janatuinen E, Pasanen P, Tarvainen R, Mustonen H, Julkunen R: Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case–control study. Scand J Gastroenterol. 2007, 42: 1395-1403. 10.1080/00365520701478758.CrossRefPubMed Udd M, Miettinen P, Palmu A, Heikkinen M, Janatuinen E, Pasanen P, Tarvainen R, Mustonen H, Julkunen R: Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case–control study. Scand J Gastroenterol. 2007, 42: 1395-1403. 10.1080/00365520701478758.CrossRefPubMed
26.
go back to reference Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ: Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002, 16: 497-506. 10.1046/j.1365-2036.2002.01197.x.CrossRefPubMed Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ: Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther. 2002, 16: 497-506. 10.1046/j.1365-2036.2002.01197.x.CrossRefPubMed
27.
go back to reference Lin KJ, Hernández-Diaz S, García Rodríguez LA: Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011, 141: 71-79. 10.1053/j.gastro.2011.03.049.CrossRefPubMed Lin KJ, Hernández-Diaz S, García Rodríguez LA: Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology. 2011, 141: 71-79. 10.1053/j.gastro.2011.03.049.CrossRefPubMed
28.
go back to reference Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991, 115: 787-796. 10.7326/0003-4819-115-10-787.CrossRefPubMed Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991, 115: 787-796. 10.7326/0003-4819-115-10-787.CrossRefPubMed
29.
go back to reference Hernández-Díaz S, García Rodríguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000, 160: 2093-2099. 10.1001/archinte.160.14.2093.CrossRefPubMed Hernández-Díaz S, García Rodríguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000, 160: 2093-2099. 10.1001/archinte.160.14.2093.CrossRefPubMed
30.
go back to reference Malmi H, Kautiainen H, Virta LJ, Farkkila N, Koskenpato J, Farkkila MA: Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther. 2014, 39: 496-506. 10.1111/apt.12620.CrossRefPubMed Malmi H, Kautiainen H, Virta LJ, Farkkila N, Koskenpato J, Farkkila MA: Incidence and complications of peptic ulcer disease requiring hospitalisation have markedly decreased in Finland. Aliment Pharmacol Ther. 2014, 39: 496-506. 10.1111/apt.12620.CrossRefPubMed
31.
go back to reference Blackburn DF, Lamb DA, McLeod MM, Eurich DT: Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. Pharmacotherapy. 2010, 30: 985-993. 10.1592/phco.30.10.985.CrossRefPubMed Blackburn DF, Lamb DA, McLeod MM, Eurich DT: Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. Pharmacotherapy. 2010, 30: 985-993. 10.1592/phco.30.10.985.CrossRefPubMed
32.
go back to reference Yeomans ND: The ulcer sleuths: The search for the cause of peptic ulcers. J Gastroenterol Hepatol. 2011, 26 (Suppl 1): 35-41. 10.1111/j.1440-1746.2010.06537.x.CrossRefPubMed Yeomans ND: The ulcer sleuths: The search for the cause of peptic ulcers. J Gastroenterol Hepatol. 2011, 26 (Suppl 1): 35-41. 10.1111/j.1440-1746.2010.06537.x.CrossRefPubMed
33.
go back to reference Ford AC, Talley NJ: Does Helicobacter pylori really cause duodenal ulcers? Yes. BMJ. 2009, 339: b2784-10.1136/bmj.b2784.CrossRefPubMed Ford AC, Talley NJ: Does Helicobacter pylori really cause duodenal ulcers? Yes. BMJ. 2009, 339: b2784-10.1136/bmj.b2784.CrossRefPubMed
34.
go back to reference Lin KJ, García Rodríguez LA, Hernández-Díaz S: Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates?. Pharmacoepidemiol Drug Saf. 2011, 20: 718-728. 10.1002/pds.2153.CrossRefPubMed Lin KJ, García Rodríguez LA, Hernández-Díaz S: Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates?. Pharmacoepidemiol Drug Saf. 2011, 20: 718-728. 10.1002/pds.2153.CrossRefPubMed
Metadata
Title
Risk of uncomplicated peptic ulcer disease in a cohort of new users of low-dose acetylsalicylic acid for secondary prevention of cardiovascular events
Authors
Ana Ruigómez
Saga Johansson
Péter Nagy
Mar Martín-Pérez
Luis A García Rodríguez
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2014
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-014-0205-y

Other articles of this Issue 1/2014

BMC Gastroenterology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.